Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Darzalex (daratumumab) is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. As a targeted therapy, Darzalex works by binding to a specific protein called CD38, which is highly expressed on the surface of myeloma cells. By doing so, it helps the immune system detect and destroy these cancer cells.
Darzalex is usually prescribed after other treatments have failed, and it can be used alone or in combination with other medications depending on the specific needs and health status of the patient. It is administered by a healthcare professional through intravenous (IV) infusion. Before you buy Darzalex, it is crucial that you talk to your healthcare provider about potential side effects and Darzalex cost.
| Fact Table | |
|---|---|
| Generic Name | Daratumumab |
| License | FDA approved |
| Bioavailability | Not available |
| Legal Status | Prescription Drug |
| Chemical Name | Daratumumab |
| Elimination Half-life | Approximately 18 days |
| Dosage (Strength) | 100 mg/5 mL or 400 mg/20 mL |
| Pregnancy | Contraindicated; should not be used during pregnancy |
| Brands | Darzalex |
| Protein Binding | Not available |
| PubChem CID | Not available |
| MedlinePlus | Not listed specifically for Darzalex |
| ChEBI | Not available |
| ATC Code | L01XC24 |
| DrugBank | DB09331 (Daratumumab) |
| KEGG | D10881 (Daratumumab) |
| Routes of Administration | Intravenous |
Darzalex is administered in a clinical setting under the supervision of a healthcare provider experienced in the use of cancer chemotherapeutic agents. The dosage and schedule depend on several factors, including the patient's medical condition, body size, and response to treatment.
Typically, Darzalex is given once a week for the first eight weeks, then every two weeks for the next 16 weeks, and thereafter every four weeks. Each session of administration can last several hours due to the need for careful monitoring and the rate of infusion.
Active Ingredient: Daratumumab.
Patients should inform their healthcare provider of any history of severe allergic reactions. Emergency medical help should be sought if symptoms of a severe allergic reaction occur, such as difficulty breathing, hives, or swelling of the face, lips, tongue, or throat.
Darzalex can make patients more susceptible to infections. Patients should report any signs of infection to their healthcare provider.
Regular blood tests are necessary to monitor blood cell counts, as Darzalex can affect these levels, potentially leading to conditions like anemia or thrombocytopenia.
Darzalex injection may interact with other medications, which can affect how it, or the other medications work or increase the risk of serious side effects. It is crucial to discuss all medications (prescription, non-prescription, and herbal products) with the healthcare provider prior to starting treatment with Darzalex. Patients should also avoid receiving live vaccines during treatment.
Common side effects include:
What is Darzalex (Daratumumab)?
Darzalex (daratumumab) is a prescription medication used to treat multiple myeloma, a type of cancer that affects plasma cells. It’s a type of drug known as a monoclonal antibody.
Is Darzalex chemotherapy?
No, Darzalex is not chemotherapy. It’s a type of biologic treatment and is sometimes called targeted therapy or immunotherapy.
How does Darzalex work?
Darzalex works by binding to a specific protein called CD38 on the surface of multiple myeloma cells, causing cell death.
How is Darzalex administered?
Darzalex is administered by infusion directly into a vein by a healthcare professional.
How long does Darzalex stay in your system?
Darzalex typically stays in your body for 3 months or longer after you stop taking it.
What are the most common side effects of Darzalex?
The most commonly reported side effects of Darzalex include nausea, diarrhea or constipation, upper respiratory infections, infusion reactions, and low blood cell counts.
How long do Darzalex side effects last?
Most mild side effects of Darzalex tend to lessen in a few days or a couple of weeks. Some serious side effects can decrease quickly with treatment but others may last a long time.
Does Darzalex cause hair loss?
Hair loss is not commonly reported as a side effect of Darzalex.
What is the success rate of Darzalex?
In a study, 47.6% of patients had a complete response or better when Darzalex was added to their treatment regimen.
What are the benefits of Darzalex?
Darzalex is effective in treating multiple myeloma in several settings. It can be used alone or in combination with other medications, depending on the type of multiple myeloma and the patient’s condition.
